sandiegojp

Author Archives

PNC and BAC TARP Warrants

A friend of mine shares his True Wealth Systems newsletter (Stansberry). Without divulging the entire content (the subject of a previous post from Travis with which I agree), they basically recommend PNC and BAC TARP warrants. I know Travis previously recommended PNC’s. I notice that the newsletter bases its recommendation on a P/B value ranging […]

Recent Author Comments

On Quickster: Introducing ScyNexis ($SCYX), a New Antimicrobial Play
$ESPR- $AMGN I would think this to be good (though limited) for ESPR: http://www.pmlive.com/pharma_news/smc_rejects_amgens_repatha_over_lack_of_outcomes_data_1041901?utm_medium=nl&utm_source=internal&mrkid=706415&mkt_tok=eyJpIjoiTWpJME1tWmtZak15TVRNMSIsI[...]
On Like A Bell You Can't Unring
(e) Resumption of clinical investigations. An investigation may only resume after FDA (usually the Division Director, or the Director's designee, with responsibility for review of the IND) has notified the sponsor that the investigation may proceed. Resump[...]
On Like A Bell You Can't Unring
$KITE - http://www.businesswire.com/news/home/20160329006379/en/Children%E2%80%99s-Hospital-Los-Angeles-Initiate-Clinical-Trial[...]
On Cyto Who?
$GILD - FYI, upcoming CEO's comment on potential areas of acquisitions: http://www.bloomberg.com/news/articles/2016-02-02/gilead-says-this-year-s-sales-will-fall-short-of-estimates?utm_medium=nl&utm_source=internal&mkt_tok=3RkMMJWWfF9wsRoku6nNdu%2FhmjTEU5z[...]
On CellCeutix: 23 Minutes with Leo Ehrlich
Re: $ACEL Thanks Dr. KSS and I am indeed well. My potential "attraction" to this IPO was, in part, due to the named underwriters as well as the fact that the company had $1.9B in revenues over the last 12 months. We'll watch and learn.[...]
On CellCeutix: 23 Minutes with Leo Ehrlich
Re: IPO Just ran across this press release and was wondering if our medical experts could chime in: Acelity Holdings, a global medical technology company developing advanced wound care and regenerative medicine, filed on Wednesday with the SEC to raise u[...]
On CellCeutix: 23 Minutes with Leo Ehrlich
Re: IPO RegenxBIO filed for an IPO. It just finished a series D round. http://www.bizjournals.com/baltimore/news/2015/08/17/venture-backed-rockville-biotech-firm-files-for.html?ana=yahoo According to the article: RegenxBio's gene therapy technology int[...]
On The Second Coming of TransEnterix?
Re: $LLY Probably because "There are some big caveats to report, as the study failed to track significant results for two other key measures: A Mini Mental State Examination (MMSE) and the Clinical Dementia Rating scale Sum of Boxes (CDR-SB)."[...]
On The Second Coming of TransEnterix?
$PARN Everyone, my sincere apologies. I DID NOT catch that the news was released on June 18th. I thought it was July 18th. Joe: thank you for correcting me and indeed the question is why hasn't it done better. The analysis of the candles stand though. How[...]
On The Second Coming of TransEnterix?
Re: $PARN - Indeed it has been in a general downtrend. Thursday's hammer candle followed by Friday by a solid white candle may indicate a trend reversal. There is a minimal volume. Whether Saturday's news is enough to lift this (significantly) higher is [...]
On The Second Coming of TransEnterix?
Re: $PARN On a subject other than $ARTH for a change, for those of you in $PARN or thinking of getting in, company announces positive results of its trial; secures a non-dilutive $11MM loan, and has hired or his hiring 40 rps to cover 6K vet clinics. http[...]
On The Second Coming of TransEnterix?
Re: $CHMA Here's another one I just received: http://seekingalpha.com/article/3323855-chiasma-ipo-consider-a-small-allocation?isDirectRoadblock=false&uprof=51[...]
On The Second Coming of TransEnterix?
Re: $DNAI I just came across this artile on an upcoming oncology-related IPO. I've never heard of this company and I don't think I could add more to what Mr. Dion states in his article. Any thoughts from Dr. KSS and other experts in the matter? http://se[...]
On Need To Know: Frontline Dispatch from the Cholesterol Wars
Re: $CYNAD/$CTH/$CYNA Hi Franklyn. It appears to be so. http://www.nasdaq.com/symbol/cynad/press-releases[...]
On Need To Know: Frontline Dispatch from the Cholesterol Wars
Re: MERS Dr. KSS, I agree with what you wrote. However, how likely are pharma companies to seize upon this opportunity to lobby for more money for vaccine development, or stocking of medicines to combat the "coming epidemic." My point being that I'm not s[...]
On Need To Know: Frontline Dispatch from the Cholesterol Wars
Re: MERS US officials calling the country grossly unprepared for a MERS epidemic. Reminds me of the Ebola scare and the annual influenza onslaught which profits many pharmas. Any ideas on how to play this latest "scare", or indeed if there is a play at al[...]
On Need To Know: Frontline Dispatch from the Cholesterol Wars
$CYNA Cynapsus Therapeutics, presently trading on Toronto Stock Exchange under ticker CTH, is IPO’ing on 6/18. The company is a specialty CNS pharmaceutical company developing and preparing to commercialize a Phase 3, fast-acting, easy-to-use, subling[...]
On Need To Know: Frontline Dispatch from the Cholesterol Wars
$NVLS Nivalis Therapeutics (previously N30 Pharmaceuticals) is due to IPO on 6/17/15 at a price range between $13-$15. It is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of product candidates for pa[...]
On A Biotech Long Idea Brought to You on Bended Knee
Hi Mark: No, there are myriad ways to get out of jury duty but I never have to use any of them. As soon as I say I was a litigator, I'm out. Unfortunately, sometimes you have to sit in the jury selection room for days before your number is called and the[...]
On A Biotech Long Idea Brought to You on Bended Knee
Re: $HALO-$ABBV Apologies for the tardy reply, I was on jury duty. While I would be indeed delighted to look up HALO's patents (a very easy task on USPTO.gov), I'm afraid that patent law is a very, very specialized area of the law. Pulling up the patents [...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

Connect with Travis

website designed by Gravity Switch